Paclib Caution For Usage

5 mL & 16.67 mL: Preparation for Intravenous Infusion: Paclitaxel for injection must be diluted prior to use for IV infusion to produce a solution containing 0.3 to 1.2 mg of paclitaxel per mL. Compatible solutions are as follows: 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, and 5% dextrose in Ringer's injection.
Visually inspect paclitaxel solution for particulate matter or discoloration prior to use. The resulting solution may show turbidity caused by the preparation solvent.
Administer through an in-line filter with a microporous membrane not greater than 0.22 micron.
Stability after reconstitution: Paclitaxel solution, when diluted as recommended, is stable for 24 hours at temperatures between 15° to 30°C.
Incompatibilities: Undiluted paclitaxel should not come in contact with plasticized polyvinyl chloride (PVC) equipment or devices. Paclitaxel should preferably be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-covered administration sets to avoid leaching from PVC infusion bags or sets.
Paclitaxel solutions are reported to be physically incompatible with the following drugs: amphotericin B, chlorpromazine hydrochloride, hydroxyzine hydrochloride, methylprednisolone, sodium succinate, and mitoxantrone hydrochloride.
Handling and Disposal Precautions: Use protective gloves when handling paclitaxel solution for injection since skin reactions (e.g., tingling, burning, erythema) may occur with accidental exposure to the drug.
Wash the affected area immediately and thoroughly with soap and water if paclitaxel comes in contact with skin/mucous membrane.
Avoid inhalation during preparation and administration of paclitaxel solutions. Inhalation may cause dyspnea, chest pain, burning eyes, sore throat, and nausea.